Most people have heard of GLP-1 by now. Ozempic. Wegovy. The medications that changed how the world thinks about weight loss. But there's a newer compound that goes further — and most people have never heard of it.
It's called Retatrutide. And the difference between the two is worth understanding — not just in terms of how they work, but in terms of the clinical outcomes they produce and who might benefit from one over the other.
GLP-1 is a single-pathway compound. It targets one receptor — the glucagon-like peptide-1 receptor — which triggers a cascade of effects: slowed gastric emptying, reduced appetite signaling, and improved insulin sensitivity.[1]
For a lot of people, that's enough. Semaglutide (the active compound in Ozempic and Wegovy) produced average weight loss of approximately 14.9% in the landmark STEP 1 trial over 68 weeks — a result that outperformed virtually every pharmacological option that came before it.[2]
The mechanism is elegant: when GLP-1 receptors are activated, your brain receives clearer satiety signals. Food noise — the constant background preoccupation with eating — quiets down. Portions naturally shrink. Impulse eating diminishes. You're not fighting willpower. You're changing biology.
Retatrutide doesn't stop at GLP-1. It's classified as a triple agonist — a single molecule that simultaneously activates three distinct hormone receptors: GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon.[3]
That third pathway — glucagon receptor activation — is what separates Retatrutide from everything else on the market. While GLP-1 works primarily by reducing caloric intake, glucagon receptor activation directly increases how much energy your body burns at rest.[4]
It's the difference between pulling one lever and pulling three simultaneously. More pathways engaged, more metabolic processes altered, stronger cumulative outcomes.
While GLP-1 reduces what goes in, glucagon receptor activation increases what gets burned. The combination produces a metabolic environment that single-pathway drugs simply cannot replicate.
Jastreboff et al., New England Journal of Medicine, 2023The Phase 2 trial of Retatrutide, published in the New England Journal of Medicine in June 2023, enrolled adults with a BMI of 30 or higher in a double-blind, randomized, placebo-controlled study. The results were striking.[3]
At 24 weeks, Retatrutide demonstrated a mean weight reduction of up to 17.5%. By the end of the 48-week treatment duration, participants achieved a mean weight reduction of up to 24.2%.[5]
The Phase 3 TRIUMPH-4 trial, results of which were published in December 2025, pushed those numbers further. Participants taking 12mg of Retatrutide lost an average of 28.7% of their body weight at 68 weeks, while patients taking a placebo lost 2.1%.[6]
To put those numbers in context: the most widely studied GLP-1 drug, semaglutide, produced approximately 14.9% weight loss in its landmark Phase 3 trial. Retatrutide at the same time point — in multiple trials — produced outcomes nearly double that figure.
| GLP-1 (Semaglutide) | Retatrutide | |
|---|---|---|
| Receptor targets | GLP-1 only | GLP-1 + GIP + Glucagon |
| Primary mechanism | Reduces appetite & slows digestion | Reduces appetite + increases resting energy expenditure |
| Phase 3 weight loss | ~14.9% (semaglutide STEP 1) | 28.7% (TRIUMPH-4, 12mg) |
| FDA approval status | Approved (Ozempic / Wegovy) | Investigational — Phase 3 ongoing |
| Dosing | Once weekly subcutaneous | Once weekly subcutaneous |
| Additional benefits studied | Cardiovascular risk reduction | Osteoarthritis, sleep apnea, liver fat, cardiovascular |
The TRIUMPH Phase 3 program encompasses more than four registrational trials, studying Retatrutide across a range of metabolic conditions. Lilly is studying Retatrutide in several Phase 3 clinical trials to evaluate its potential efficacy and safety in obesity and overweight with at least one weight-related medical problem, type 2 diabetes, knee osteoarthritis, moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.[7]
One particularly notable finding comes from a 2024 Nature Medicine study examining Retatrutide's effect on liver fat in patients with metabolic dysfunction-associated steatotic liver disease. The mean relative change from baseline in liver fat at 24 weeks was −42.9% at 1mg, −57.0% at 4mg, −81.4% at 8mg, and −82.4% at 12mg — compared to +0.3% with placebo.[8] An 82% reduction in liver fat at the therapeutic dose is a finding that significantly expands what we understand this class of compound to be capable of.
It's important to be honest about what we know and what we don't. Retatrutide is still an investigational compound. The Phase 3 TRIUMPH program is ongoing, with additional data expected through 2026. It has not yet received FDA approval for any indication.
The safety profile observed in trials is consistent with other incretin-based therapies — the most common adverse events include nausea, diarrhea, constipation, and vomiting, particularly at higher doses and during dose escalation. These events are generally transient and rarely led to treatment discontinuation in trial participants.[6]
For people who have not seen the results they expected from GLP-1 therapy alone, Retatrutide represents a genuinely different mechanism — not just a more potent version of the same drug. The glucagon receptor component creates a metabolic environment that single-pathway GLP-1 drugs simply cannot replicate.
GLP-1 is a tool. Retatrutide is a more powerful version of that tool — with a broader mechanism, more pathways engaged, and clinical outcomes that have consistently exceeded what we expected.
The research is evolving rapidly. What's clear from the existing data is that the weight loss results produced by triple-agonist compounds represent a meaningful step forward for metabolic medicine — one that a growing number of researchers believe may redefine what's possible for people who haven't responded adequately to existing options.
For the full breakdown of GLP-1 peptides, how they work, and what the current research says, explore the BioRefined research library.